Meeting NewsVideo

VIDEO: Phase 2b results positive for Orasis presbyopia-correcting drops

SAN FRANCISCO — Elad Kedar, CEO of Orasis Pharmaceuticals, discusses results of a phase 2b trial of the company’s CSF-1 eye drop formulation for presbyopia correction at the Ophthalmology Innovation Summit preceding the American Academy of Ophthalmology annual meeting. Positive safety, durability and efficacy results were demonstrated, he said.

SAN FRANCISCO — Elad Kedar, CEO of Orasis Pharmaceuticals, discusses results of a phase 2b trial of the company’s CSF-1 eye drop formulation for presbyopia correction at the Ophthalmology Innovation Summit preceding the American Academy of Ophthalmology annual meeting. Positive safety, durability and efficacy results were demonstrated, he said.

    See more from Ophthalmology Innovation Summit